Genomind vs YouScript (2026)
Both turn a genetic result into prescribing guidance and they are built around different halves of that sentence. Genomind owns the laboratory: a clinician ordered swab across 26 to 27 genes covering both metabolism and drug response, with a centre of gravity in mental health and ordering built into the record system. YouScript owns the computation: it takes the genotype and the entire medication regimen together and calculates the cumulative effect, on the argument that binary interaction alerting breaks down once a patient is on a dozen drugs, and it holds the only prospective randomised controlled trial located in this category. If you already have genotyping and need the interpretation to survive polypharmacy, YouScript. If you need the test itself, Genomind, and read its own account of what the result does and does not establish.
- The laboratory half is transparent and specific: a clinician ordered buccal swab genotyped across 26 to 27 genes, split between metabolism and response, with analytical accuracy published and the gene list named.
- Ordering and result review run inside the record system, so a prescriber can request the test and read the interpretation without leaving the chart.
- The company states the limitations of its own product more plainly than most vendors in this index, which is the right posture for a test whose clinical utility evidence is contested.
- It computes the cumulative effect of the whole regimen together with the genotype rather than checking drug pairs one at a time, which is the failure mode of conventional interaction alerting on a patient taking a dozen medications.
- It holds the only prospective randomised controlled trial located in this category, published in a peer reviewed journal, which is a materially stronger evidence position than a test with contested utility.
- Reach follows the medication list rather than a specialty, covering more than 2,000 drugs across four named record systems including a route into Canadian practice.
This comparison is published by AI Health Index, an independent research platform that compares healthcare AI vendors objectively. Genomind and YouScript are each graded against the same capability taxonomy, from each vendor's own public materials and the regulatory record, under the AI Health Index verification standard. No vendor pays for placement, and no vendor has reviewed this page. How this evidence is graded
Plain facts
| Fact | Genomind | YouScript |
|---|---|---|
| Primary category | Medication Safety & Prescribing | Medication Safety & Prescribing |
| Founded | Not recorded | 2016 |
| Headquarters | King of Prussia, Pennsylvania, United States | Seattle, Washington, United States |
| Website | genomind.com | youscript.com |
Side by Side
Each record in one paragraph
Written to be quoted whole. Each paragraph states what the AI Health Index verified about the vendor, with the caveats attached. Generated from this pair’s live capability grades, so it moves when a grade moves.
The AI Health Index records no top capability grade for Genomind on any axis it scores. Set against YouScript, Genomind grades higher on Commercial Transparency. Its thinnest published disclosure sits on several axes, including AI Centrality, HIPAA and BAA Posture and Security Certifications and Trust Center. Grades reflect evidence the AI Health Index could verify at the last review, so a low grade records disclosure the vendor has not published rather than a capability it has been shown to lack.
Source: AI Health Index, August 2026
The AI Health Index records no top capability grade for YouScript on any axis it scores. Set against Genomind, YouScript grades higher on AI Centrality and Clinical and Operational Evidence. Its thinnest published disclosure sits on several axes, including HIPAA and BAA Posture, Security Certifications and Trust Center and AI Governance and Bias Disclosure. Grades reflect evidence the AI Health Index could verify at the last review, so a low grade records disclosure the vendor has not published rather than a capability it has been shown to lack.
Source: AI Health Index, August 2026
Questions buyers ask
Should we choose Genomind or YouScript?
On the axes where the AI Health Index separates them, Genomind grades higher on Commercial Transparency, and YouScript grades higher on AI Centrality and Clinical and Operational Evidence. YouScript leads on the greater share of scored axes, but the split means the decision turns on which constraint is binding rather than on an overall winner.
Where do Genomind and YouScript differ most?
The widest separation the AI Health Index records between Genomind and YouScript is on Commercial Transparency, where Genomind grades C and YouScript grades D. That axis sits in the Commercial group, so it should carry the most weight for a buyer whose binding constraint is contracting, scope and what the price actually covers.
Where do Genomind and YouScript grade the same?
The AI Health Index grades Genomind and YouScript the same on several axes, including Autonomy and Oversight Model, Model and Technology Transparency and Model Supply Chain Disclosure. Neither holds an advantage the index can evidence on those axes, so they should not carry weight in a selection between these two.
What have Genomind and YouScript not disclosed?
At the last review, at least one of Genomind and YouScript published thin or absent detail on several axes, including AI Centrality, HIPAA and BAA Posture and Security Certifications and Trust Center. The AI Health Index treats an absent disclosure as a gap in the public record rather than a failure of the product, so these are the axes to get in writing during diligence instead of inferring from the grade.
Related comparisons
Other published head to head assessments involving these vendors or their closest peers. The full set for this category is on the Clinical Decision Support page.
Pharmacogenomic data is a category apart and both records carry the same exposure: a genetic result is permanent, cannot be revoked once disclosed, and carries implications for biological relatives who never consented to anything. Neither vendor publishes a security attestation, trust centre, HIPAA statement or business associate terms, which is a serious gap for that data type.
Neither publishes performance by ancestry, which is the specific fairness question in pharmacogenomics, since allele frequencies and the evidence base behind gene drug pairs both vary by ancestral population and a panel validated mainly in one population will be less informative in others. Neither publishes pricing.